Health & Medicine Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health & Medicine Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Renal Cell Carcinoma
Monoclonal antibodies may be key in treatment for renal cell carcinoma
October 27th, 2003
Monoclonal antibodies may be key in treatment for renal cell carcinoma. According to a study from Netherlands, "Despite intensive efforts to develop an effective treatment, once renal cell carcinoma (RCC) has metastasized, treatment options are limited. "This tumor is not sensitive to radiotherapy and is resistant to chemotherapy, and treatment with biologic response modifiers (interleukin-2, interferon) leads to low response rates. Monoclonal antibodies (mAb) selected for high tumor specificity might provide new treatment possibilities for RCC," wrote E. Oosterwijk and colleagues, University of Nijmegen Medical Center. The...
Source: Health & Medicine Week (2003-10-27)
|
